VG Life Sciences Secures Patent For Cell-Protective IBD Treatment

VG Life Sciences Secures Patent For Cell-Protective IBD Treatment
vgVG Life Sciences (VGLS), a biotechnology company committed to developing therapies for infectious and autoimmune diseases, recently announced that the U.S. Patent and Trademark Office (USPTO) has issued the company a Patent No. 8906846 covering a new method to treat inflammatory bowel disease (IBD) via administrating a CLIP-inducing agent. This patent, along with the company's already-established intellectual properties, demonstrates VG Life Science's continued efforts to advance the potential of CLIP (class II-associated invariant chain peptide) as a groundbreaking solution to chronic inflammatory conditions. The company's research projects are based on the concept that when an endothelial or epithelial cell of the mucosal tract is lacking its own CLIP, the cell will be vulnerable to mediated cell death, which consequently causes autoimmune diseases such as IBD. The company's new therapeutic technology utilizes findings revealing that CLIP provides a kind of armor to the cell's surface, which shields it from mediated cell death. Agents that promote CLIP -- exogenous CLIP included -- have been proven very useful in the treatment of autoimmune
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *